PAINREFORM LTD. Logo

PAINREFORM LTD.

Specialty pharma developing extended-release drugs for post-operative pain management.

PRFX | US

Overview

Corporate Details

ISIN(s):
IL0011651580
LEI:
Country:
United States of America
Address:
65 YIGAL ALON ST., 6744316 TEL AVIV
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PainReform Ltd. is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics for improved pain management. The company develops treatments using its proprietary extended-release drug-delivery system, designed to prolong efficacy, reduce adverse effects, and increase patient comfort. Its lead product candidate, PRF-110, is an oil-based solution that is instilled directly into a surgical wound to provide localized and extended post-operative analgesia. This approach aims to reduce the need for systemically administered opiates. The company is also strategically expanding its drug delivery platform into other therapeutic areas, such as ophthalmology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PAINREFORM LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PAINREFORM LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PAINREFORM LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Medios AG Logo
Compounding patient-specific therapies and supplying specialty pharma for complex conditions.
Germany
ILM1
Develops cord blood stem cell therapies for osteoarthritis & infant lung disease, plus banking.
South Korea
078160
MediWound Ltd. Logo
Develops enzymatic therapies for non-surgical tissue repair in burns and chronic wounds.
United States of America
MDWD
Medizen Humancare Inc Co., Ltd Logo
Offers DTC genetic testing and genomic analysis for personalized disease risk prediction.
South Korea
236340
Medy-Tox Inc. Logo
Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.
South Korea
086900
MeiraGTx Holdings plc Logo
Develops genetic medicines for eye, salivary gland, and CNS disorders using gene regulation tech.
United States of America
MGTX
Meito  Sangyo  Co., Ltd. Logo
Produces food products and specialty chemicals for industrial and pharmaceutical applications.
Japan
2207
Merck & Co., Inc. Logo
A global biopharma developing innovative medicines, vaccines, and animal health products.
United States of America
MRK
Mereo BioPharma Group plc Logo
A clinical-stage biopharma developing and commercializing novel therapies for rare diseases.
United States of America
MREO
Mersana Therapeutics, Inc. Logo
Developing innovative antibody-drug conjugates using proprietary platforms to treat cancer.
United States of America
MRSN

Talk to a Data Expert

Have a question? We'll get back to you promptly.